Genmab A/S (GMAB) - Total Assets

Latest as of September 2025: Dkr7.02 Billion DKK ≈ $1.10 Billion USD

Based on the latest financial reports, Genmab A/S (GMAB) holds total assets worth Dkr7.02 Billion DKK (≈ $1.10 Billion USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore debt repayment capacity of Genmab A/S to assess how comfortably operating cash covers total debt obligations.

Genmab A/S - Total Assets Trend (2002–2024)

This chart illustrates how Genmab A/S's total assets have evolved over time, based on quarterly financial data. See GMAB book value for net asset value and shareholders' equity analysis.

Genmab A/S - Asset Composition Analysis

Current Asset Composition (December 2024)

Genmab A/S's total assets of Dkr7.02 Billion consist of 60.8% current assets and 39.2% non-current assets.

Asset Category	Amount (DKK)	% of Total Assets
Cash & Equivalents	Dkr0.00	21.5%
Accounts Receivable	Dkr6.59 Billion	14.4%
Inventory	Dkr62.00 Million	0.1%
Property, Plant & Equipment	Dkr0.00	0.0%
Intangible Assets	Dkr12.34 Billion	26.9%
Goodwill	Dkr2.54 Billion	5.5%

Asset Composition Trend (2002–2024)

This chart illustrates how Genmab A/S's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see GMAB stock market capitalisation.

Show as percentage

Key Asset Composition Facts

Current vs. Non-Current Assets: Genmab A/S's current assets represent 60.8% of total assets in 2024, a decrease from 89.6% in 2002.
Cash Position: Cash and equivalents constituted 21.5% of total assets in 2024, up from 16.0% in 2002.
Tangible vs. Intangible: Intangible assets (including goodwill) make up 31.0% of total assets, an increase from 4.0% in 2002.
Asset Diversification: The largest asset category is intangible assets at 26.9% of total assets.

Genmab A/S Competitors by Total Assets

Key competitors of Genmab A/S based on total assets are shown below.

Company	Country	Total Assets
Ascendis Pharma AS NASDAQ:ASND	USA	$2.01 Billion
Halozyme Therapeutics Inc NASDAQ:HALO	USA	$2.22 Billion
Akero Therapeutics Inc NASDAQ:AKRO	USA	$1.01 Billion
Beijing Tiantan Biological Products Corp Ltd SHG:600161	China	CN¥16.55 Billion
Zealand Pharma A/S CO:ZEAL	Denmark	Dkr16.46 Billion
Verona Pharma PLC ADR NASDAQ:VRNA	USA	$572.87 Million
Immunitybio Inc NASDAQ:IBRX	USA	$518.99 Million
Tibet Cheezheng Tibetan Medicine Co Ltd SHE:002287	China	CN¥6.66 Billion

Genmab A/S - Liquidity and Working Capital Analysis

Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.

Key Liquidity Metrics

Metric	Current	1 Year Ago	5 Years Ago
Current Ratio	6.03	5.17	15.00
Quick Ratio	6.01	5.15	15.20
Cash Ratio	0.00	0.00	0.00
Working Capital	Dkr3.73 Billion	Dkr19.11 Billion	Dkr17.54 Billion

Genmab A/S - Advanced Valuation Insights

This section examines the relationship between Genmab A/S's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.

Key Valuation Metrics

Current Price-to-Book Ratio	3.24
Latest Market Cap to Assets Ratio	0.39
Asset Growth Rate (YoY)	29.8%
Total Assets	Dkr45.81 Billion
Market Capitalization	$17.91 Billion USD

Valuation Analysis

Below Book Valuation: The market values Genmab A/S's assets below their book value (0.39x), which may indicate investor concerns about asset quality or future growth.

Rapid Asset Growth: Genmab A/S's assets grew by 29.8% over the past year, indicating significant expansion of the company's resource base.

Annual Total Assets for Genmab A/S (2002–2024)

The table below shows the annual total assets of Genmab A/S from 2002 to 2024.

Year	Total Assets	Change
2024-12-31	Dkr45.81 Billion ≈ $7.17 Billion	+29.82%
2023-12-31	Dkr35.29 Billion ≈ $5.52 Billion	+17.17%
2022-12-31	Dkr30.12 Billion ≈ $4.71 Billion	+22.30%
2021-12-31	Dkr24.63 Billion ≈ $3.85 Billion	+16.48%
2020-12-31	Dkr21.14 Billion ≈ $3.31 Billion	+39.61%
2019-12-31	Dkr15.14 Billion ≈ $2.37 Billion	+78.99%
2018-12-31	Dkr8.46 Billion ≈ $1.32 Billion	+28.14%
2017-12-31	Dkr6.60 Billion ≈ $1.03 Billion	+26.05%
2016-12-31	Dkr5.24 Billion ≈ $819.56 Million	+34.23%
2015-12-31	Dkr3.90 Billion ≈ $610.58 Million	+36.13%
2014-12-31	Dkr2.87 Billion ≈ $448.51 Million	+65.56%
2013-12-31	Dkr1.73 Billion ≈ $270.91 Million	+2.28%
2012-12-31	Dkr1.69 Billion ≈ $264.86 Million	+8.21%
2011-12-31	Dkr1.56 Billion ≈ $244.77 Million	-36.96%
2010-12-31	Dkr2.48 Billion ≈ $388.26 Million	+11.71%
2009-12-31	Dkr2.22 Billion ≈ $347.58 Million	-31.83%
2008-12-31	Dkr3.26 Billion ≈ $509.89 Million	-17.68%
2007-12-31	Dkr3.96 Billion ≈ $619.38 Million	+119.37%
2006-12-31	Dkr1.80 Billion ≈ $282.35 Million	+31.68%
2005-12-31	Dkr1.37 Billion ≈ $214.41 Million	+7.75%
2004-12-31	Dkr1.27 Billion ≈ $199.00 Million	+7.78%
2003-12-31	Dkr1.18 Billion ≈ $184.64 Million	-25.46%
2002-12-31	Dkr1.58 Billion ≈ $247.69 Million	--

About Genmab A/S

CO:GMAB Denmark Biotechnology

Market Cap

$17.91 Billion

Dkr114.48 Billion DKK

Market Cap Rank

#1406 Global

#8 in Denmark

Share Price

Dkr1858.50

Change (1 day)

+0.79%

52-Week Range

Dkr1357.50 - Dkr2251.00

All Time High

Dkr3295.00